December 6, 2016 11:28 AM EST
Bioregnum
Pharma
Opinion

Is the US bio­phar­ma in­dus­try head­ed for a turn­ing point in 2017?

Three months ago, Brent Saun­ders fired a shot across the bow of the USS Big Phar­ma, pledg­ing to lim­it Al­ler­gan’s an­nu­al price in­crease on …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

A service from the Financial Times